TLR4 and tuberculosis: The vaccine contains an adjuvant formulation CIA09, composed of DOTAP-based cationic liposomes and the TLR4 agonist dLOS, which enhances antibody and cell-mediated immune responses to tuberculosis protein antigens and inactivated JEV vaccine [42,43].